Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Abstract Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC. Increasingly, these biomarker-guided systemic therapies...

Descrición completa

Detalles Bibliográficos
Main Authors: Luis A. Godoy, Joy Chen, Weijie Ma, Jag Lally, Kyra A. Toomey, Prabhu Rajappa, Roya Sheridan, Shirish Mahajan, Nicholas Stollenwerk, Chinh T. Phan, Danny Cheng, Robert J. Knebel, Tianhong Li
Formato: Artigo
Idioma:English
Publicado: BMC 2023-01-01
Series:Biomarker Research
Subjects:
NSCLC
Resectable
Neoadjuvant
Immune checkpoint inhibitor (ICI)
Targeted therapy
Precision oncology
Acceso en liña:https://doi.org/10.1186/s40364-022-00444-7

Internet

https://doi.org/10.1186/s40364-022-00444-7

Títulos similares